Latest filings (excl ownership)
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
3 May 24
8-K
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
3 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
25-NSE
Exchange delisting
29 Apr 24
PRE 14A
Preliminary proxy
17 Apr 24
8-K
Entry into a Material Definitive Agreement
17 Apr 24
8-K
Regulation FD Disclosure
15 Apr 24
S-1/A
IPO registration (amended)
2 Apr 24
S-8
Registration of securities for employees
1 Apr 24
8-K
AEON Biopharma Announces Redemption of Public Warrants
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Mar 24
8-K
Entry into a Material Definitive Agreement
19 Mar 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
16 Feb 24
S-1/A
IPO registration (amended)
22 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
AEON Biopharma Reports Third Quarter 2023 Financial Results
13 Nov 23
S-1/A
IPO registration (amended)
20 Oct 23
8-K
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
19 Oct 23
8-K
Changes in Registrant's Certifying Accountant
2 Oct 23
S-1
IPO registration
18 Aug 23
8-K/A
Financial Statements and Exhibits
11 Aug 23
8-K
Index to Financial Statements
27 Jul 23
8-K
Corporate Presentation July 2023
24 Jul 23
CERT
Certification of approval for exchange listing
21 Jul 23
25
Voluntary exchange delisting
21 Jul 23
8-A12B
Registration of securities on exchange
21 Jul 23
10-Q
2023 Q2
Quarterly report
21 Jul 23
S-4MEF
Addition of securities to prior registration
18 Jul 23
425
Business combination disclosure
17 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Jul 23
425
Business combination disclosure
11 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Jul 23
425
Business combination disclosure
5 Jul 23
8-K
Departure of Directors or Certain Officers
5 Jul 23
425
Business combination disclosure
30 Jun 23
DEFA14A
Additional proxy soliciting materials
30 Jun 23
Latest ownership filings
3
Seongsoo Park
18 Apr 24
4/A
Change in insider ownership (amended)
16 Apr 24
4
Change in insider ownership
12 Apr 24
4
Change in insider ownership
26 Mar 24
4
Shelley B Thunen
21 Mar 24
4
ROBERT J PALMISANO
21 Mar 24
4
Marc Forth
21 Mar 24
4
Chad Oh
21 Mar 24
4
JOST FISCHER
21 Mar 24
4
Eric G Carter
21 Mar 24
4
Alexander Blair Wilson
21 Mar 24
SC 13G
Polar Asset Management Partners Inc.
14 Feb 24
SC 13G/A
Empyrean Capital Partners, LP
14 Feb 24
SC 13D/A
Strathspey Crown Holdings Group, LLC
22 Aug 23
4
Shelley B Thunen
16 Aug 23
4
ROBERT J PALMISANO
16 Aug 23
4
JOST FISCHER
16 Aug 23
4
Eric G Carter
16 Aug 23
4
Change in insider ownership
14 Aug 23
3
Initial statement of insider ownership
31 Jul 23
SC 13D
Strathspey Crown Holdings Group, LLC
31 Jul 23
SC 13G
Atalaya Capital Management LP
31 Jul 23
SC 13D
Daewoong Co., Ltd
28 Jul 23
3
Initial statement of insider ownership
28 Jul 23
4
ROBERT J PALMISANO
26 Jul 23
4
Alexander Blair Wilson
24 Jul 23
4
Eric G Carter
24 Jul 23
4
Chad Oh
24 Jul 23
4
Marc Forth
24 Jul 23
4
JOST FISCHER
24 Jul 23
3
JOST FISCHER
24 Jul 23
3
Shelley B Thunen
24 Jul 23
3
Alexander Blair Wilson
24 Jul 23
3
PETER A REYNOLDS
24 Jul 23
3
Chad Oh
24 Jul 23
3
Eric G Carter
24 Jul 23
3
Marc Forth
24 Jul 23
SC 13G/A
Saba Capital Management, L.P.
20 Jul 23
SC 13G/A
GLAZER CAPITAL, LLC
12 Jun 23
4
Change in insider ownership
31 Mar 23